OCUGEN, INC. Finance Lease, Right-of-Use Asset, Amortization
OCUGEN, INC. (OCGN) reported Finance Lease, Right-of-Use Asset, Amortization of $3.19 thousand for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2019-11-12
- OCUGEN, INC. finance lease, right-of-use asset, amortization for the quarter ending 2019-09-30 was $3.19K.
- OCUGEN, INC. finance lease, right-of-use asset, amortization for the quarter ending 2019-06-30 was $3.19K.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month |
|---|---|---|---|
| 2019-09-30 | $3.19K 10-Q · filed 2019-11-12 | $6.38K derived: sum of 2 quarters · filed 2019-11-12 | $9.57K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $3.19K 8-K/A · filed 2019-10-07 | $6.38K 8-K/A · filed 2019-10-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |